目的 探讨桂龙咳喘宁片联合布地奈德治疗小儿急性支气管炎的临床效果。方法 选取2021年3月—2023年3月在运城市中心医院治疗的急性支气管炎患儿148例，随机分为对照组（74例）和治疗组（74例）。对照组患儿雾化吸入布地奈德混悬液，1 mL加入生理盐水2 mL，1次/d。治疗组患儿在对照组基础上口服桂龙咳喘宁片，2次/d，4片/次。两组患儿均连续治疗7 d。观察两组患儿临床疗效，比较治疗前后两组患儿临床症状改善情况及白细胞计数（WBC）、C反应蛋白（CRP）和白细胞介素-17（IL-17）水平。结果 治疗后，治疗组总有效率为93.24%，明显高于对照组（81.08%，P＜0.05）。治疗后，治疗组咳嗽消失时间、体温恢复正常时间和咳痰消失时间均短于对照组（P＜0.05）；治疗后，两组WBC、CRP和IL-17水平较治疗前明显降低（P＜0.05），且治疗组降低幅度明显大于对照组（P＜0.05）。结论 桂龙咳喘宁片联合布地奈德治疗小儿急性支气管炎能帮助患儿快速控制临床症状，降低体内的炎症反应，疗效令人满意，且安全性好。

Objective To investigate the therapeutic effect of Guilong Kechuanning Tablets combined with budesonide in treatment of acute bronchitis in children. Methods Children (148 cases) with acute bronchitis in Yuncheng Central Hospital from March 2021 to March 2023 were randomly divided into control (74 cases) and treatment (74 cases) group. Children in the control group were administered with Budesonide Suspension for inhalation, 1 mL added into normal saline 2 mL, once daily. Children in the treatment group were po administered with Guilong Kechuanning tablets on the basis of the control group, 4 tablets/time, twice daily. Children in two groups were treated for 7 d. After treatment, the clinical evaluation was evaluated, and the time of symptom relief, the levels of WBC, CRP and IL-17 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 93.24%, which was significantly higher than that of the control group (81.08%, P＜0.05). After treatment, the disappearance time of cough, body temperature and sputum in the treatment group were shorter than those in the control group (P＜0.05). After treatment, the levels of WBC, CRP, and IL-17 in both groups were significantly lower than those before treatment (P＜0.05), and the reduction range in the treatment group was significantly greater than that in the control group (P＜0.05). Conclusion Guilong Kechuanning Tablets combined with budesonide in treatment of acute bronchitis in children can help children with acute bronchitis quickly control clinical symptoms and reduce inflammatory reaction in vivo with good efficacy and safety.

R974

山西省卫生健康委员会科研课题（2020188）